HC Wainwright & Co. Reiterates Neutral on Akebia Therapeutics, Maintains $2 Price Target
Portfolio Pulse from Benzinga Newsdesk
HC Wainwright & Co. analyst Ed Arce reiterated a Neutral rating on Akebia Therapeutics (NASDAQ:AKBA) and maintained a $2 price target.
June 02, 2023 | 3:43 pm
News sentiment analysis
Sort by:
Descending
NEUTRAL IMPACT
Akebia Therapeutics (NASDAQ:AKBA) receives a Neutral rating from HC Wainwright & Co. analyst Ed Arce, with a maintained $2 price target.
The news of HC Wainwright & Co. analyst Ed Arce reiterating a Neutral rating on Akebia Therapeutics and maintaining a $2 price target is directly related to the company. However, as it is a reiteration of a previous rating and not a change, the short-term impact on the stock price is expected to be neutral.
CONFIDENCE 90
IMPORTANCE 70
RELEVANCE 100